Serum 25-Hydroxyvitamin D and Breast Cancer in the Military: A Case-control Study Utilizing Pre-diagnostic Serum
Abstract
Background. The objective of this study was to test whether a relationship exists between prediagnostic serum levels of 25-hydroxyvitamin D (25(OH)D) and subsequent risk of breast cancer in an active-duty U.S. military cohort. Methods. 600 incident cases of female breast cancer were matched to 600 female controls as part of a nested case control study. Conditional logistic regression was used to assess the relationship between serum 25(OH)D concentration and breast cancer risk, while controlling for race and age Findings. The quintile cutpoints were < 15, 15-21.7, 27.4-35.1, and > 35.1 ng/ml. There was a trend toward an inverse association between serum 25(OH)D and odds of breast cancer. In pairs in which serum was collected less than 90 days before diagnosis of the case, women in the highest quintile of serum 25(OH)D had 70% lower estimated risk of breast cancer (odds ratio 0.30, 95% confidence interval 0.12-0.74, p < 0.01 for contrast) compared to those in the lowest. Interpretation. The favorable association of serum 25(OH)D with risk of breast cancer suggest that the influence of serum 25(OH)D in risk of breast cancer in adult women was strongest during the final few doublings of the tumor mass preceding diagnosis in this population. Further epidemiological research, including cohort studies, of the relationship between serum 25(OH)D status and breast cancer risk and its timing should be undertaken to confirm this association.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 08, 2013
- Accession Number
- ADA618084
Entities
People
- Caroline A. MacEra
- Cedric F. Garland
- Christopher I. Kane
- Deborah L. Wingard
- Edward Doerr Gorham
- J. K. Parsons
- John E. Alcaraz
- Ronald Horst
- Sharif B. Mohr
Organizations
- Naval Health Research Center